Private Advisor Group LLC increased its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 7.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,914 shares of the exchange traded fund’s stock after acquiring an additional 1,448 shares during the quarter. Private Advisor Group LLC’s holdings in SPDR S&P Biotech ETF were worth $1,835,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Raymond James Financial Services Advisors Inc. raised its holdings in SPDR S&P Biotech ETF by 13.9% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 240,709 shares of the exchange traded fund’s stock worth $18,578,000 after buying an additional 29,346 shares during the period. Newman Dignan & Sheerar Inc. raised its holdings in SPDR S&P Biotech ETF by 0.6% during the 2nd quarter. Newman Dignan & Sheerar Inc. now owns 8,260 shares of the exchange traded fund’s stock worth $638,000 after buying an additional 50 shares during the period. IFP Advisors Inc raised its holdings in SPDR S&P Biotech ETF by 18.3% during the 3rd quarter. IFP Advisors Inc now owns 12,081 shares of the exchange traded fund’s stock worth $1,046,000 after buying an additional 1,868 shares during the period. WealthPLAN Partners LLC raised its holdings in SPDR S&P Biotech ETF by 1,107.2% during the 2nd quarter. WealthPLAN Partners LLC now owns 10,527 shares of the exchange traded fund’s stock worth $812,000 after buying an additional 9,655 shares during the period. Finally, Meridian Wealth Management LLC raised its holdings in SPDR S&P Biotech ETF by 25.4% during the 3rd quarter. Meridian Wealth Management LLC now owns 7,028 shares of the exchange traded fund’s stock worth $608,000 after buying an additional 1,425 shares during the period.

Shares of SPDR S&P Biotech ETF (NYSEARCA XBI) traded up $2.11 during mid-day trading on Thursday, reaching $82.06. 472,681 shares of the company’s stock traded hands. SPDR S&P Biotech ETF has a 52-week low of $58.66 and a 52-week high of $88.98.

WARNING: This article was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://theolympiareport.com/2017/12/07/spdr-sp-biotech-etf-xbi-position-lifted-by-private-advisor-group-llc.html.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with Analyst Ratings Network's FREE daily email newsletter.